Humacyte, Inc. (HUMA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Humacyte reported revenue of $2.0M. Net income was -$40.8M (a -2003.6% net margin), or -$0.26 per diluted share. Gross margin was -376.1% and operating margin was -5306.0%. Operating activities generated -$105.0M of cash, leaving -$105.9M of free cash flow. At fiscal year end, Humacyte held $116.4M in total assets against $113.3M in total liabilities, including $50.5M of cash and equivalents.
Open the full interactive Humacyte financials → Quarterly statements, key ratios, valuation history and price charts.
Humacyte Key Stats
| Share Price | $0.36 |
|---|---|
| Market Cap | $84.1M |
| 52-Week Range | $0.36 – $1.81 |
| Shares Outstanding | 234.2 million (basic, 2026 Q2) |
Humacyte Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $2.0M |
| Cost of Goods Sold | — | — | — | — | $9.7M |
| Gross Profit | — | — | — | — | -$7.7M |
| Operating Income | -$81.2M | -$84.6M | -$100.0M | -$114.4M | -$108.1M |
| Pre-Tax Income | -$26.5M | -$12.0M | -$110.8M | -$148.7M | -$40.8M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$26.5M | -$12.0M | -$110.8M | -$148.7M | -$40.8M |
| Diluted EPS | -$0.66 | -$0.12 | -$1.07 | -$1.26 | -$0.26 |
Humacyte Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $753,000 | $467,000 | $495,000 | $406,000 |
| Net Income | -$17.5M | -$24.8M | -$17.6M | -$36.8M |
| Diluted EPS | -$0.11 | -$0.16 | -$0.09 | -$0.16 |
Humacyte Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $217.5M | $149.8M | $80.4M | $44.9M | $50.5M |
| Current Assets | $229.3M | $154.2M | $83.3M | $47.9M | $67.8M |
| Total Assets | $286.5M | $204.3M | $128.2M | $137.9M | $116.4M |
| Current Liabilities | $11.1M | $19.6M | $18.4M | $20.0M | $18.4M |
| Total Long-Term Debt | $30.0M | $28.9M | $38.6M | $63.4M | $35.4M |
| Total Liabilities | $164.4M | $87.4M | $114.7M | $190.5M | $113.3M |
| Shareholders' Equity | $122.2M | $116.9M | $13.5M | -$52.7M | $3.1M |
Humacyte Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$81.2M | -$71.1M | -$73.3M | -$98.1M | -$105.0M |
| Cash From Investing | -$8.2M | $4.8M | -$173,000 | -$1.6M | -$884,000 |
| Cash From Financing | $267.0M | -$1.4M | $4.5M | $114.2M | $61.5M |
| Free Cash Flow | -$81.4M | -$72.1M | -$75.6M | -$99.7M | -$105.9M |
Figures from Humacyte's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Humacyte financials page for every line item.
Humacyte Company Profile
| Ticker | HUMA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Durham, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001818382 |
Frequently Asked Questions
What was Humacyte's revenue in fiscal 2025?
Humacyte (HUMA) reported revenue of $2.0M for fiscal 2025.
What is Humacyte's annual revenue history?
Humacyte's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $2.0M.
What was Humacyte's net income in fiscal 2025?
Humacyte reported net income of -$40.8M for fiscal 2025.
What was Humacyte's earnings per share (EPS) in fiscal 2025?
Humacyte's diluted EPS was -$0.26 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Humacyte generate in fiscal 2025?
Humacyte generated -$105.9M of free cash flow in fiscal 2025.
What was Humacyte's revenue last quarter?
In its most recent reported quarter (2026 Q2), Humacyte reported revenue of $406,000.
How much debt does Humacyte have?
Humacyte reported $35.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Humacyte are outstanding?
Humacyte reported a weighted average of 234.2 million basic shares outstanding in 2026 Q2.
What is Humacyte's market cap?
Based on its latest closing price, Humacyte (HUMA) has a market capitalization of about $84.1M.
When does Humacyte's fiscal year end?
Humacyte's fiscal year end, as registered with the SEC, is December 31.
Where is Humacyte headquartered?
Humacyte lists its business address in Durham, North Carolina in its SEC filings.
Humacyte Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →